
pmid: 34954720
Purpose of review The objective of this review is to discuss if chronic kidney disease (CKD) leads to chronic heart failure (CHF), and does worsening CHF lead to CKD progression and how a new medication class can modify the risk of both outcomes. Recent findings Sodium-glucose cotransporter 2 (SGLT2) inhibitors are similarly effective on cardiovascular (CV) - and kidney-related outcomes in the presence of CV and CKD. Summary SGLT2 inhibitors can reduce the risk of CHF events and CKD progression, and may have synergistic effects in patients with cardiorenal syndrome.
Heart Failure, Male, Diabetes Mellitus, Type 2, Humans, Female, Renal Insufficiency, Chronic, Kidney, Sodium-Glucose Transporter 2 Inhibitors
Heart Failure, Male, Diabetes Mellitus, Type 2, Humans, Female, Renal Insufficiency, Chronic, Kidney, Sodium-Glucose Transporter 2 Inhibitors
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
